Integration of smoking cessation into standard treatment for patients receiving opioid agonist therapy who are smoking tobacco: protocol for a randomised controlled trial (ATLAS4LAR)

BACKGROUND: About 85% of patients receiving opioid agonist therapy (OAT) for opioid dependence are smoking tobacco. Although smoke-related pulmonary diseases are significant contributors to morbidity and mortality, few smoking cessation interventions are evaluated within this group, and few OAT pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Druckrey-Fiskaaen, Karl Trygve, Furulund, Einar, Daltveit, Jan Tore, Vold, Jørn Henrik, Lid, Torgeir Gilje, Madebo, Tesfaye, Fadnes, Lars Thore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382815/
https://www.ncbi.nlm.nih.gov/pubmed/35978355
http://dx.doi.org/10.1186/s13063-022-06560-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382815/
https://www.ncbi.nlm.nih.gov/pubmed/35978355
http://dx.doi.org/10.1186/s13063-022-06560-x

Ejemplares similares